News
News
View the latest company news from Surface Ophthalmics.
-
March 13, 2024
Surface Ophthalmics Announces New Leadership with Richard Lindstrom, MD, and Renewed Vision for Addressing Critical Unmet Needs of Dry Eye Syndrome Patients
-
July 21, 2021
Surface Ophthalmics Announces $25 Million Private Round of Fundraising
-
May 6, 2021
Surface Ophthalmics’ Landmark Chronic Dry Eye Study Reaches 50% Enrollment Milestone
-
March 31, 2021
Surface Ophthalmics Announces Preeya K. Gupta, MD as Chief Medical Advisor
-
February 4, 2021
Surface Ophthalmics Announces First Patient Dosed in Phase II Trial for SURF-200 for Acute Dry Eye
-
January 27, 2021
Surface Ophthalmics Announces First Patient Dosed in Landmark Head-to-Head Phase II Trial for SURF-100 for Chronic Dry Eye Disease
-
January 21, 2021
Surface Ophthalmics Announces Positive Top-Line Results from Phase II Trial for SURF-201 (Betamethasone 0.2% in Klarity® vehicle) for the Treatment of Post-Cataract Surgery Pain and Inflammation
-
January 7, 2021
Surface Ophthalmics Previews Important Clinical Progress in 2021
-
October 1, 2020
Surface Pharmaceuticals Further Strengthens Board of Directors as Clinical Programs Advance
-
September 3, 2020
Surface Pharmaceuticals Strengthens Leadership Team as Clinical Programs Advance in Eye Care
-
May 15, 2018
Surface Pharmaceuticals, Inc. Announces $20 Million Series A Financing From Flying L Partners